Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Author:
Affiliation:
1. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX; and
2. Division of Hematological Malignancies,
3. Division of Chemical Therapetuics, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/121/23/4655/1366002/4655.pdf
Reference49 articles.
1. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.;Nakao;Leukemia,1996
2. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.;Kottaridis;Blood,2001
3. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.;Fröhling;Blood,2002
4. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.;Thiede;Blood,2002
5. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.;Abu-Duhier;Br J Haematol,2000
Cited by 332 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Acute myeloid leukemia patients with high-risk karyotypes benefit from decitabine in combination with modified CAG;2024-01-08
2. Epigenetic biomarkers;Epigenetics in Human Disease;2024
3. FLT3 targeting in the modern era: from clonal selection to combination therapies;International Journal of Hematology;2023-12-19
4. Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia;Annals of Hematology;2023-11-17
5. Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024;Acta Haematologica;2023-10-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3